News – Page 1179 – Endpoints News

AstraZeneca shuffles the deck, deals out a new hand for two troubled drugs

9 years ago

Kleiner Perkins is lining up a new $400M tech fund

9 years ago

Fresh from Epirus disaster, Munshi chops staff to remake Arena Pharma

9 years ago

Exorcising Martin Shkreli’s ghost, KaloBios steps out of Ch. 11 and back into the biotech business

9 years ago

Ampio shares are routed (again) as its PhIII do-over for osteoarthritis flops

9 years ago

Where the money is: Biotech’s megahubs command VC's billions

9 years ago

Boehringer Ingelheim axes 725 jobs in U.S. reorganization

9 years ago

One of Shire’s top pipeline prospects fails a PhII study among preemies

9 years ago

Bruised but standing, Syros braves its way through a $50M IPO

9 years ago

Novartis shoots for early OK of a ‘breakthrough’ blood cancer drug after reversing organ damage in trial

9 years ago

The biotech IPO feast flags as investors lose their appetite for R&D risk

9 years ago

What PDUFA date? Clovis shares surge as PARPs get trendy on Wall Street

9 years ago

Neoantigens beckon Merck into a $200M cancer collaboration with Moderna

9 years ago

Galena implodes as trial monitors call a halt to a failed PhIII cancer study

9 years ago

Tesaro rockets up after PARP inhibitor aces PhIII study and R&D rivalry intensifies

9 years ago

Esperion tanks on warning that the road to an FDA decision could be much, much longer than they thought

9 years ago

Two flops in two weeks for Marinus Pharmaceuticals' ganaxolone

9 years ago

Troubled Infinity axes 100 staffers, shutters trials and rewards top execs after AbbVie walks away from deal

9 years ago

In latest setback for stem cell sector, Celyad fails PhIII— and the biotech claims a victory

9 years ago

Novartis inks a $2.5B bispecific cancer drug development alliance with Xencor

9 years ago

Regulus craters after FDA slaps a hold on hep C RNA drug following 2nd case of jaundice

9 years ago

Third time the charm? Analyst says a marketing decision is “imminent” for Sarepta’s Duchenne drug eteplirsen

9 years ago

Bristol-Myers’ nivolumab grabs its sixth breakthrough designation as new links to autoimmune diseases creep up

9 years ago

GW Pharma’s rally rolls on as cannabinoid drug scores again in PhIII Epidiolex anti-convulsive study

9 years ago

First page Previous page 1176 1177 117811791180 Next page Last page